DOCSLIB.ORG

Company Report Hong Kong Equity Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Company Report Hong Kong Equity Research Wednesday, October 15, 2014 China Merchants Securities (HK) Company Report Hong Kong Equity Research Jintian Pharma Group (2211 HK) Jonathan HSU Marley Ngan 852-31896135 852-31896635 Value of strong branding and platform; initiate with BUY [email protected] [email protected] ■ Leading private pharma retail & distribution group in NE China ■ A Licensed Brand Manager (LBM) creating a high-GM multi-brand sales platform and implementing a streamlined Direct Supply Initiation system. Entry barrier is further established with channel and CRM. ■ Significant re-rating potential for this single-digit-PER stock with BUY 30% EPS CAGR FY13-16E. BUY-rated with 101% upside to 12-m TP. Previous NA Unique business model in a unique market Price HK$2.83 Jintian adopts a unique LBM plus Direct Supply business model on its 12-month Target Price HK$5.68 (+101%) fast-expanding networks of retail (mainly based in NE China) and national (Potential upside) distribution. Positioned as a multi-brand sales platform operator, Jintian Previous NA license-in third-party brands and directly supplies to retailers/distributors from manufacturers. It further offers value-adds: brand/channel/customer Price Performance relationship management. Its Direct Supply model not only integrates (%) margins by cutting traditional intermediaries, but also lowers upstream 40 2211 HSI Index raw material costs by leveraginig collective bargaining power given Jintian’s control over downstream order quantity and pricing. 20 Multiple catalysts drive long-term profitable growth 0 Management is targeting 30% net profit growth for both FY14E and -20 FY15E on 1) increase in number of directly-owned retail pharmacies via -40 acquisition and self-build, 2) expanding national distribution network, 3) Dec/13 Apr/14 Jul/14 expanding high-margin product portfolio by carrying more branded products with exclusive distribution rights and LBM, 4) emerging new e- Source: Bigdata commerce platform and O2O business. % 1m 6m 12m 2211 HK (6.1) 18.1 23.6 HSI (5.9) 0.6 (0.3) Strong 1H14 results indicate strong growth momentum 1H14 net profit grew 48% YoY driven by 1) 40% revenue growth thanks to 34% increase in member no. and 19% higher average spending, 2) Pharmaceutical & Healthcare 3.4-ppt GM rise thanks to better sales mix towards LBM products and Hang Seng Index 23,048 products utilizing Direct Supply model. OPM/NM improved 1.2/0.6-ppt. HSCEI 10,255 Key Data Valuation 52-week range (HK$) 1.88-3.65 We set our TP on target 15x FY15E PER or 0.5x FY15E PEG using 30% Market cap (HK$ mn) 5,600 FY13-16E EPS growth, approx. 50% discount to HK pharma sector avg. Avg. daily volume (mn) 11.74 BVPS (HK$) 1.23 Financials Shareholdings Structure RMB m, Dec-YE 2012 2013 2014E 2015E 2016E Asia Health 45.1% AMG 16.1% Revenue 2,326 3,323 4,540 5,934 7,407 Target Asset Management 5.1% Growth (%) 58% 43% 37% 31% 25% No. of shares outstanding 2,000M Net profit 214 355 478 606 779 Free float 46.0% Growth (%) 19% 66% 35% 27% 29% EPS (RMB) 0.11 0.18 0.24 0.30 0.39 DPS (RMB) NA NA 0.05 0.06 0.08 P/E (x) 21.18 12.75 9.48 7.48 5.81 P/B (x) 7.21 1.84 1.57 1.32 1.10 ROE (%) 36% 16% 18% 19% 21% Source: Company data, CMS (HK) To access our research reports on the Bloomberg terminal, type CMHK <GO> 1 2014 年 10 月 15 日(星期三) 公司报告 招商证券（香港）有限公司 许瑞生 颜宇翾 金天医药集团 (2211 HK) 852-31896135 852-31896635 强大的品牌和平台价值；首次覆盖，给予“买入”评级 [email protected] [email protected] ■ 中国东北的领头民营医药零售与分销企业 ■ 特许品牌经销商（LBM）实现多品牌高毛利销售平台，实施精简直供 首次覆盖 体系。通过渠道及客户关系管理进一步提升行业门槛 ■ 市盈率为个位数，2013-2016年EPS年复合增长率30％，拥有强大的估 值提升潜力。给予买入评级，12个月目标价上涨空间为101％ 买入 前次评级 NA 独特的市场，独一无二的商业模式 股价 HK$2.83 金天采用特许品牌经销商及直供商业模式，快速扩张零售（主要在中国东 12个月目标价 北地区）和全国配送网络。其定位是多品牌销售运营商，金天拥有第三方 HK$ 5.68 （+101%） 品牌许可，可直接从厂家供货给零售/分销商。公司更提供增值服务项目： (上涨空间) 品牌/渠道/客户关系管理。其直供模式不仅削减了传统销售的中间商成分， 前次目标价： NA 金天还可以通过控制下游订单数和销售价格（控销）提升议价能力，降低 上游原料成本。 股价表现 (%) 多重催化剂推动长期盈利增长 40 金天医药集团 恒生指数 管理层对 和 年的目标是净利润成長 ％，通过 ）增加自营零售 2014 2015 30 1 20 药店数量（来自收购和自建），2）扩大全国分销网络，3）获得更多独家 产品经销权和特许品牌从而扩大高毛利产品组合，4）建立新的电子商务平 0 台和O2O业务。 -20 2014上半年良好业绩显示强劲增长动力 -40 2014上半年净利润同比增长48％，动力来自1）40％的收入增长得益于 2013/12 2014/04 2014/07 ％的会员数目增加及平均消费上升 ％， ）毛利率上升 个百分点得 34 19 2 3.4 资料来源：贝格数据 益于特许品牌产品更好的销售组合和直供的销售模式。营业利润率/ 净利 % 1m 6m 12m 润率分别上升1.2/0.6个百分点。 2211 HK (6.1) 18.1 23.6 HSI (5.9) 0.6 (0.3) 估值 行业：医药、医疗服务 我们目标价对应于15倍2015年预期市盈率或0.5倍2015年PEG，基于 恒生指数 23048 2013-2016年EPS年复合增长率30％，较港股医药行业均值约有50％的折 国企指数 10255 价。 重要数据 52周股价区间（港元） 1.88-3.65 港股市值（百万港元） 5,600 日均成交量（百万股） 11.74 每股净资产（港元） 1.23 主要股东 盈利预测及估值 Asia Health 45.1% 人民币百万元 2012 2013 2014E 2015E 2016E AMG 16.1% 营业额 2,326 3,323 4,540 5,934 7,407 Target Asset Management 5.1% 同比增长(%) 58% 43% 37% 31% 25% 总股数 （百万股） 2,000 净利润 214 355 478 606 779 自由流通量 46.0% 同比增长(%) 19% 66% 35% 27% 29% 每股盈利(元) 0.11 0.18 0.24 0.30 0.39 每股股息(元) NA NA 0.05 0.06 0.08 市盈率(X） 21.18 12.75 9.48 7.48 5.81 市净率(X) 7.21 1.84 1.57 1.32 1.10 ROE(%) 36% 16% 18% 19% 21% 资料来源：公司资料,招商证券（香港）预测 彭博终端报告下载: CMHK <GO> 2 Wednesday, October 15, 2014 Contents Focus Charts.................................................................................................................................................................. 5 Figure 1: Strong 31% revenue CAGR FY13-16E .......................................................................................................... 5 Figure 2: Margin expansion trend .................................................................................................................................. 5 Figure 3: Strong growth of high-GM Retail biz segment ............................................................................................... 5 Figure 4: Healthy growth of Distribution biz segment .................................................................................................... 5 Figure 5: Key driver: High-GM prem branded products ................................................................................................ 5 Figure 6: Key driver: High-GM Direct Supply Model...................................................................................................... 5 Valuation ........................................................................................................................................................................ 6 Key risks ........................................................................................................................................................................ 6 Company Analysis ......................................................................................................................................................... 8 - Unique market; capturing opportunities in a rapidly-developing market 8 - Unique business model; creating win-win for all partners 8 - Unique business strategy; moving forward with speed, scale, and innovation 8 Key growth drivers……………………………………………………………………………………………………………… 11 Financial Analysis ........................................................................................................................................................ 12 Company Profile .......................................................................................................................................................... 16 Appendix: Macro Charts .............................................................................................................................................. 19 To access our research reports on the Bloomberg terminal, type CMHK <GO> 3 Wednesday, October 15, 2014 Investment thesis BUY-rated with 12-month target price HK$5.68, a 101% upside We expect Jintian’s leading market positioning, unique business model, and entrepreneurial management team to generate 31% revenue CAGR and 30% EPS CAGR FY13-16E, capturing attractive growth Multiple growth drivers to opportunities in the fragmented and under-developed pharma retail and generate 31% revenue CAGR distribution market in particularly Northeast China. Key growth drivers and 30% EPS CAGR FY14E-16E. include: 1) organic growth in SSSG, customer/member base and average spending, 2) retail pharmacy network expansion via M&A and self-build, 3) high-margin (over 60% GM) product portfolio expansion via licensing-in brands and obtaining products with exclusive distribution rights, and 4) increasing implementation of the Direct Supply model. Emerging e-commerce business initiative could become a new key growth driver in the future. Our model estimates are conservative as we factor in business risks associated with branding efforts, product sourcing, and M&A. We expect gradual margin uptrend FY13-16E as a result. As such, margin upside exists if sales of new high-margin products ramp up faster than expected, and if further Direct Supply model is applied. Investment positives We like the combination of Jintian’s multi-brand sales platform and its extensive retail and distribution presence. It further creates value (and set up entry barrier) by aggressively focusing on licensing-in and managing brands, streamlining supply chain, managing the channel and Multi-brand sales platform with customer relationship. The company’s scale and track record in higher-margin Direct Supply on successfully identifying and seizing business opportunities in a fast- top of retail and distribution consolidating, rapidly-changing growth market, will help achieve long networks that are expanding term sustainable profitable growth. rapidly with scale. Jintian’s home market of pharma retail and distribution market in Northeast China is growing at over 20% annually, vs. decelerating growth for China overall towards mid-teens.
Load more

Recommended publications
  • Inside This Issue
    1 December 23, 2014 – Issue 122 INSIDE THIS ISSUE China Green Food Expo to be Held in Nanchang China Green Food Expo to be The seventh China Green Food Expo is to be held in Nanchang, Held in Nanchang Jiangxi province. Companies from more than 30 provinces will attend the Expo with thousands of attendees to the event. Jan-Oct China Health Insurance The event is co-held by Ministry of Commerce and Jiangxi local Premium Exceeded CNY 130bn government. CFDA: Cosmeceuticals Should not The Expo tends to promote the economic rise of middle area of Promote Itself as Medicines the country and the opening-up of Jiangxi province. The event will include the food expo and a cooperation seminar joined by Shi Jiazhuang to Crack Down on state-run companies with local food providers and vendors. Illegal Health Food and Cosmetics The Expo mainly features low-carbon industry and green food. It will cover six indoor exhibiting rooms with food companies from Amorepacific Taps Surging more than 30 provinces. Overseas vendors from Australia, Demand for Midrange Beauty America, Russia and Thailand will also bring food to the local Products consumers who will attend the expo. （Source: Food Safety Daily) China Nepstar: A Bitter Pill For Investors Jan-Oct China Health Insurance Premium Exceeded CNY 130bn Herbal Berberine Boosts Brown Fat Activity Premium income of health insurance exceeded CNY 136.656 billion in the first 10 months of this year, growing 45.25% year on year, according to China Insurance Regulatory Commission. Premium income of life insurance companies grew 19.36% year on year.
    [Show full text]
  • China Digest
    China Digest China by numbers Round-up of business news, current issues, • 13,548 meters - combined height of and M&A analysis skyscrapers built in China in 2014 • 3 – number of world’s 10 tallest buildings Q1 2015 built in Wuxi city in 2014 • 7% - share of global freshwater in China In the news … (vs. 20% of world population) • 7 - of China’s ten most polluted cities are Subsidies cut for non-electric vehicles [Auto] in Hebei province The Ministry of Finance reports it is to reduce subsidies for traditional vehicles in • 30,000 - number of TV drama episodes an effort to boost the country’s renewable energy vehicle market. A program to build made in China annually charging infrastructure will also be accelerated. Aside from helping reduce urban pollution levels, the subsidy cut could encourage take-up of electric and hybrid • 14 - number of countries bordering China vehicles and boost domestic manufacturers such as BYD. (Caixin) • 648 million - China's online population • 280 million - number of people in China Growth of China O&G consumption to slow in 2015 [Energy] without safe drinking water China’s oil & gas consumption is expected to see slower growth this year, with falling • $1,831 - President Xi Jinping’s monthly global crude prices providing an opportunity for more energy sector reforms, salary according to the Economic and Technology Research Institute of the country’s • $1.2billion - annual US drug exports to largest O&G producer, China National Petroleum Corp. Chinese oil demand will China grow 3% year-on-year to 534 million metric tons in 2015, compared to growth of • $119.6 billion - China's actual use of 3.3% (to 516 million tons) in 2014, it said.
    [Show full text]
  • China Nepstar Chain Drugstore Ltd
    +44 20 8123 2220 [email protected] China Nepstar Chain Drugstore Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis https://marketpublishers.com/r/CCAE3DA5C6BBEN.html Date: September 2021 Pages: 50 Price: US$ 499.00 (Single User License) ID: CCAE3DA5C6BBEN Abstracts China Nepstar Chain Drugstore Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between China Nepstar Chain Drugstore Ltd. and its competitors. This provides our Clients with a clear understanding of China Nepstar Chain Drugstore Ltd. position in the Retail Industry. The report contains detailed information about China Nepstar Chain Drugstore Ltd. that gives an unrivalled in-depth knowledge about internal business- environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history. Another part of the report is a SWOT-analysis carried out for China Nepstar Chain Drugstore Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it. The China Nepstar Chain Drugstore Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios China Nepstar Chain Drugstore Ltd.
    [Show full text]
  • Annual Report 2017
    ANNUAL REPORT 2017 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) PROFIT ATTRIBUTABLE TO OWNERS OF THE PARENT RMB13,161.3 million Intelligence in Action 2017 marked the 25th anniversary of Fosun and our strongest financial year ever. Over these years, being a global company with Chinese roots, we are well-prepared for future opportunities with our strong industrial operations. We are dedicated to pursuing our strategy of “Centered around Family, Deeply Rooted in China, Innovating a Global Happiness Ecosystem”. We have hired some of the very best global talent to execute our customer-to-maker (C2M) strategy. We are fully confident that through Fosun’s core operations, innovative technologies and ONE Fosun ecosystem spanning over 35 million families, our C2M strategy will further advance and create value for our customers. In addition, through our newly launched Youle Customer Loyalty Program (“youlè”), Fosun aims at linking its products and services in our health, happiness and wealth ecosystems to create one-stop solutions for 1 billion families around the world. “A journey of a thousand miles begins with a single step”. In the past 25 years, Fosun has continued to be bold yet humble, building its success with stability and consistency. Looking ahead, we must continue to pursue our C2M strategy, focus on core operations, and develop our pioneering technology and innovation platform so we can become not just a global company with Chinese roots, but a global operator of world-class products and services. Furthermore, Fosun’s senior management and global partners* will step up their efforts to carry out more philanthropic works, with a view to doing more practical and effective initiatives to achieve our mission of helping our family customers live in a healthier, happier and wealthier life.
    [Show full text]
  • Sinopharm Group: 2H14 NDR Takeaways: Margin Expansion To
    Sinopharm Group | March 25, 2015 MORGAN STANLEY RESEARCH March 25, 2015 MORGAN STANLEY ASIA LIMITED+ Yolanda Hu Sinopharm Group [email protected] +852 2848-5649 Bin Li 2H14 NDR Takeaways: Margin Expansion [email protected] +852 2239-7596 Isabella Zhao to Continue [email protected] +852 2848-5887 Industry View Stock Rating Price Target Attractive Overweight HK$34.00 Sinopharm Group ( 1099.HK , 1099 HK ) China Healthcare / China Stock Rating Overweight Sinopharm’s solid sales growth and operating leverage are likely to Industry View Attractive continue in 2015, despite the uncertain policy outlook for the Price target HK$34.00 Up/downside to price target (%) 15 Healthcare industry. We find the stock attractive at 18x our revised Shr price, close (Mar 24, 2015) HK$29.50 2015e EPS. Reiterate OW. 52-Week Range HK$34.50-19.72 Sh out, dil, curr (mn) 2,568 Healthy 2015 sales outlook: Given decelerating GDP growth expected in Mkt cap, curr (mn) Rmb60,695 EV, curr (mn) Rmb78,243 2015, mgmt looks for growth of the end-user market to slow to 12%, and for Avg daily trading value (mn) HK$133 the distribution industry to grow 14-15%. Management remains confident about achieving its sales target of 3-5% above the market average. Fiscal Year Ending 12/14 12/15e 12/16e 12/17e ModelWare EPS (Rmb) 1.11 1.32 1.51 1.70 Margin improvement to continue in 2015, ... This is the first quarter that Prior ModelWare EPS 1.10 1.29 1.44 1.58 (Rmb) Sinopharm has recorded faster profit growth than sales growth, mainly due to: Consensus EPS (Rmb)§ 1.10 1.30 1.55 1.50 1) internal integration; 2) economies of scale; 3) optimizing customer mix Revenue, net (Rmb 200,131 235,469 272,701 313,245 (more direct sales to hospitals), and 4) more focus on the quality of growth.
    [Show full text]
  • Sinopharm Group Co Ltd PERFORM 12-18 Mo
    EQUITY RESEARCH INITIATION OF COVERAGE November 15, 2012 CHINA/HEALTHCARE Stock Rating: Sinopharm Group Co Ltd PERFORM 12-18 mo. Price Target NA Dominant Leader in a Growing/Consolidating 1099.HK - HKSE HK$24.90 Industry; Initiating with Perform 3-5 Yr. EPS Gr. Rate 21% SUMMARY 52-Wk Range HK$27.45-HK$16.76 We are initiating coverage of Sinopharm (1099.HK) with a Perform rating. China's Shares Outstanding 2,403.0M pharma distribution is growing rapidly and consolidating gradually from a competitive Float 828.0M to an oligopolistic industry. Sinopharm, China's largest pharmaceutical distributor, Market Capitalization HK$59,825.4M represents the best investment vehicle to gain exposure, in our view. In recent years, Avg. Daily Trading Volume 2,452,955 it has gained market share, and we believe it will continue to do so with strong Dividend/Div Yield HK$0.19/0.76% government backing, ample capital and economies of scale. Although most pharma wholesalers experience margin erosion, Sinopharm's margins have been relatively Book Value HK$6.73 stable. We believe it can grow revenue/net income at 21.5%/21.4% CAGRs during Fiscal Year Ends Dec 2011-17. However, its fair valuation keeps us on the sideline initially. We would look 2012E ROE 9.0 % to become more constructive as valuation becomes more attractive. LT Debt HK$5,229.0M Preferred NM KEY POINTS Common Equity HK$21,528M ■ Absolute Dominance. China's No. 1 pharma distributor, Sinopharm has more Convertible Available No than 10% market share in an industry that's growing at a double-digit rate and, interestingly, consolidating at the same time, backed by government support.
    [Show full text]
  • “Profiting from China's Fast-Growing Retail Pharmaceutical Industry”
    Trading symbol: CYXN (OTCBB) China Yongxin Pharmaceuticals, Inc. 927 Canada Court City of Industry, CA 91748 - USA Phone: (626) 581-9098 Fax: (626) 581-9138 Email: [email protected] www.chinayongxin.com Overview September 2008 China Yongxin Pharmaceuticals, Inc. is a 15-year-old enterprise that was founded in Changchun, Jilin province, China. China Yongxin’s Chinese enterprise is known as Yongxin brand. The company is a producer, distributor and retailer of pharmaceutical products. Today, the company has five subsidiaries including 93 stores. “Profiting from China’s fast-growing retail Public Company Stats pharmaceutical industry” Ticker: CYXN CIK: 0001087848 SIC Code: 5912 China Yongxin Pharmaceuticals’ revenues for the six month period ending June State of Incorporation: Delaware 30, 2008 grew 30% as compared to revenues for the six month period ending June 30, 2007. The Company’s sales for the six month period ending June 30, Price (9/01/2008): $0.54 2008 were $29.6 million compared to $22.9 million for the six month period 52-wk high/low: $0.32/$3.00 ending June 30, 2007. Net Comprehensive Income rose by 32.7% to $2.32 Av. volume (90-day): 21,200 million for the six month period ending June 30, 2008 from $1.75 million for the Shares outstanding: 31.0 million six month period ending June 30, 2007. Market cap: $16.74 million Cash on 6/30/08: $1.09 million Revenues (6 mos):* $29.57 million Gross Profit (6 mos):* $5.38 million Net Profit (6 mos):* $2.32 million Rev Growth (6 mos):* 30% Net Comprehensive Income Growth:* * 32.7% On the Web: www.yongxinchina.com *Six month period ending June 30, 2008 **Compared to Six month period ending June 30, 2007 Sources: Company filings, Hoover’s Market Drivers • China’s overall GDP grew at over 11% per the latest readings; • Retail pharmaceutical sales are projected to grow at 20% per year to over $30B by 2011; • A strong network of over3,500 retail buyers of the company’s products; • China’s up and coming middle class is demanding higher quality medicines and natural and organic alternatives.
    [Show full text]
  • Outlook on China's Pharmaceutical Distribution Market 2019-2025 - Cross- Border Integration of Pharmaceuticals & E-Commerce Continues
    Source: Research and Markets November 13, 2019 11:58 ET Outlook on China's Pharmaceutical Distribution Market 2019-2025 - Cross- border Integration of Pharmaceuticals & e-Commerce Continues Dublin, Nov. 13, 2019 (GLOBE NEWSWIRE) -- The "China Pharmaceutical Distribution Industry Report, 2019- 2025" report has been added to ResearchAndMarkets.com's offering. This report highlights the following: China pharmaceutical distribution industry (development environment, status quo, market size, market structure, competitive pattern and development trends) China drug retailing market (market size, gross margin, and net margin, quantity, the share of medical insurance designated stores, per customer transaction, and comparison of operating results between major drug retailers) 20 Chinese pharmaceutical distribution companies (operation, revenue structure, gross margin, development strategy, etc.). In 2018, the Market was Worth RMB2,194.5 Billion, a 9.6% Rise From RMB2,001.6 Billion in 2017, of Which Drug Retailing Market Size Ranged at RMB437.7 Billion in 2018, Compared With RMB400.3 Billion in 2017. China's pharmaceutical distribution industry has sustained steady growth over the years By product, western medicine is prevailing in the Chinese pharmaceutical distribution market, sweeping 73.2% of total sales in 2018; by region, the east and the central south of China take larger shares, a combined 62.1% in 2018. In China, a competitive pattern has taken shape that national drug distributors led by Sinopharm, China Resources Pharmaceutical Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group, and regional distribution companies such as Nanjing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun Pharmaceutical, Zhejiang Int'l Group, Realcan Pharmaceutical, Guangzhou Liuzhou Pharmaceutical and Luyan Phapma, compete with each other.
    [Show full text]
  • Procter & Gamble Teams with Teva in OTC Market
    OTC31-03-11p1&24FIN.qxd 31/3/11 07:09 Page 1 31 March 2011 COMPANY NEWS 3 Procter & Gamble teams Walgreens to acquire 3 drugstore.com Novartis UK plans 3 to move Consumer with Teva in OTC market OTC turnover disappoints 4 at Celesio Germany’s Bionorica 6 rocter & Gamble has signed a ‘master ledge, plus a network of mass-retail partners. pushes into the UK Pagreement’with Teva Pharmaceutical Yanai’s counterpart at Procter & Gamble, Galenica’s Vifor OTC unit 7 Industries to create a consumer healthcare Bob McDonald, pointed out that Teva’s exten- reports gains partnership, including a joint venture that sive portfolio in categories such as allergy,gas- NBTY reports loss 8 will bring together each firm’s OTC port- trointestinal and respiratory would provide a in wake of takeover folio. However, Procter & Gamble will re- pipeline of potential prescription-to-non-pre- Linola and Vagisan lift 9 tain full control of its North American OTC scription switches that could either become new sales at Dr Wolff operations. lines or extensions to Procter & Gamble brands Alliance Pharma poised 10 The joint venture – in which Procter & such as Metamucil, Pepto-Bismol and Vicks. to acquire Anbesol brand Gamble will hold 51% and Teva 49% – will Details of the collaboration are currently be- SEEK to auction 10 combine the two companies’ OTC operations ing finalised. Subject to regulatory approval, the cough-drug rights in all markets outside of North America and two firms expect to close the deal this autumn. will have annual sales of more than US$1 bil- The chief executive officer of the joint ven- GENERAL NEWS 11 lion (C700 million) on formation.
    [Show full text]
  • Acquisition of Finished Drug Businesses Reduces Bulk Exposure
    June 27, 2012 COMMENT China Pharmaceutical Group (1093.HK) HK$2.05 Equity Research Acquisition of finished drug businesses reduces bulk exposure News China Pharm has announced the acquisition of three finished drug companies from its parent for a total consideration of HK$8.98 bn (HK$2.271 bn equity and HK$6.708 bn in convertible bonds). Total 2011 NPAT of the acquired companies was Rmb314 mn (HK$383mn) in 2011 (vs HK$233 mn for China Pharm). China Pharm also stated that net tangible assets of the acquired companies will be no less than HK$950 mn at completion. Assuming an HK$600mn/HK$800mn earnings contribution as guided by China Pharm for target companies in 2012E/13E, we calculate EPS accretion will be HK$0.103/0.137 on a fully converted basis post share allotment and CB issuance respectively, which gives an acquisition P/E multiple of 15x/11x for 2012/13E respectively. Analysis The acquisitions are: (1) CSPC OYY, owning four pharma manufacturing sites with GMP standards and four bulk drugs production lines meeting global standards. It manufactures over 200 pharma products, including Azithromycin capsules, Alendronate sodium tablets and Levoamlodipine Maleate tablets. NPAT was Rmb114mn in 2010 and Rmb142mn in 2011, with 2011 year-end NAV of Rmb220mn. The OYY subsidiaries’ NPAT were Rmb-0.468mn/Rmb0.295mn in 2010/2011. (2) CSCP NBP, engaged primarily in the manufacture of drugs for the central nervous system (CNS), e.g. cerebrovascular drug Butylphthalide Soft Capsules. NPAT was Rmb13.99mn/Rmb105.5mn in 2010/2011, with NAV at end of 2011 at Rmb235mn.
    [Show full text]
  • 2013 Outlook 10 December 2012 Health Care Industry Update
    Deutsche Bank Markets Research Asia Industry Date China 2013 Outlook 10 December 2012 Health Care Industry Update Jack Hu, Ph.D Research Analyst Anticipate healthy revenue growth (+852) 2203 6208 [email protected] and modest margin pressure Healthy sector growth with modest margin pressure in 2013 Top picks We estimate 20-22% growth for the drug sector and 19% growth for the Sino Biopharmaceutical Buy medical device sector in 2013, driven primarily by healthy growth in medical (1177.HK),HKD3.72 reimbursement funding and completion of the infrastructure build-up cycle, China Shineway (2877.HK),HKD12.16 Buy respectively. We expect operating margin erosion to continue, due largely to Mindray Medical (MR.N),USD34.47 Buy rising sales and marketing expenses. We reiterate our top picks, namely Shineway (2877.HK), Sino Biopharm (1177.HK) and Mindray Medical (MR.N). Companies Featured Catalysts in 2013 We expect the following positive catalysts: 1) continuous demand growth, Sino Biopharmaceutical Buy (1177.HK),HKD3.72 demonstrated by growth acceleration of in-/out-patient visits to hospitals; 2) 2011A 2012E 2013E 2013 NRDL expansion, as more drugs should be reimbursed; and 3) new GMP P/E (x) 20.1 22.3 19.0 inspection for injectables by YE13, since sector consolidation is likely to ensue. EV/EBITDA (x) 8.9 9.7 8.2 We also anticipate the following uncertainties in 2013: 1) 2013 RDL tender, Price/book (x) 3.0 4.2 3.9 which could have a negative impact on drug pricing; and 2) hospital reform, which will affect prescription volumes, a larger risk compared with pricing.
    [Show full text]
  • Healthcare in China Entering Uncharted Waters
    Healthcare in China Entering uncharted waters Healthcare Healthcare in China Entering uncharted waters September 2012 2 Preface The Chinese government is committed to their capabilities, and aspire to strategic improvement of the healthcare system and alliances and international expansion. development of the healthcare industry Insurance companies and healthcare as clear strategic priorities. Reforms providers are also beginning to benefit from the announced in 2009 set the ambitious goal government’s resolute steps towards opening of providing universal access to effective, up the market. By allowing private companies safe, and low-cost healthcare by 2020. to play a larger role, the government will enable The 12th Five-Year Plan, issued in March a significant inflow of new entrants who are 2011, encourages innovation throughout eager to tap into the primary opportunities in the biomedical industry, broadly defined as health insurance, private hospitals and clinics, covering pharmaceuticals, vaccines, medical and in the services such as healthcare IT that products and traditional Chinese medicine. underpin them. Its designation as a ‘strategic industry’ leads to government support through significant Many of the ingredients are in place for flows of public funds and favorable policy- the continuation of strong growth of the changes, many of which have yet to be healthcare sector. We believe however that conceived and articulated. These various the path ahead will be more challenging, policies will offer extensive opportunities for reflecting the ambition and the scale participants in every sector of the industry. of the transformation under way. In the words of vice-premier Li Keqiang, China’s Spending on healthcare for the China’s healthcare system has entered ‘uncharted vast population is on a fast track to reach waters’.
    [Show full text]